242 avsnitt

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast PVI, PeerView Institute for Medical Education

    • Vetenskap

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

    Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

    Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

    Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.

    • 27 min
    "Joseph D. Khoury, MD, FCAP - Visualizing Progress for TP53-Mutant AML: A Pathology-Guided Journey Through Diagnostic Principles and Modern Treatment"

    "Joseph D. Khoury, MD, FCAP - Visualizing Progress for TP53-Mutant AML: A Pathology-Guided Journey Through Diagnostic Principles and Modern Treatment"

    Go online to PeerView.com/WNX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert pathologist discusses the prognostic relevance of TP53 mutations, current diagnostic tools and principles for capturing TP53-mutated acute myeloid leukemia (AML), and new developments with innovative therapy for TP53-mutated AML. Upon completion of this accredited CE activity, participants should be better able to: Identify the diagnostic, prognostic, and therapeutic implications of TP53-mutant AML, Recommend appropriate molecular/pathology testing to establish diagnosis of TP53-mutant AML in order to inform the evidence-based selection of treatment, Summarize evidence on the use of novel antibody and targeted options for the management of TP53-mutant AML.

    • 21 min
    "Susana Banerjee, MBBS, MA, FRCP, PhD / William J. Gradishar, MD, FASCO, FACP / Maha Hussain, MD, FACP, FASCO

    "Susana Banerjee, MBBS, MA, FRCP, PhD / William J. Gradishar, MD, FASCO, FACP / Maha Hussain, MD, FACP, FASCO

    Go online to PeerView.com/VHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of improved understanding of the genetic mechanisms underlying solid tumors, PARP inhibitors are now validated treatments for patients with ovarian, prostate, breast, and pancreatic cancers. Targeting DNA damage response (DDR) mutations, which have an important role in tumorigenesis, PARP inhibitors are now being studied in other cancers, as well as in combination with immunotherapies and other agents. Approvals of PARP inhibitors have, in some cases, brought with them approvals of companion diagnostics or complementary diagnostic tests. Join a panel of oncology experts for a PeerView MasterClass providing in-depth education on PARP inhibitors, including the rationale for their use, the latest efficacy and safety data in a variety of tumor types, and investigational uses of these agents. Didactic presentations will be supplemented with a practicum session featuring guidance and clinical perspectives on diagnostic testing, dosing considerations, managing AEs associated with PARP inhibitors, and selecting patients for clinical trial enrollment. Upon completion of this accredited CE activity, participants should be better able to: Discuss the rationale for use and the expanding role of PARP inhibitors in the treatment of different cancers, including malignancies of the ovaries, prostate, breast, and pancreas, Describe the efficacy and safety profiles of PARP inhibitors and the role of diagnostic testing in guiding patient selection across a range of cancers, Implement appropriate strategies for integrating PARP inhibitors, either through approved indications or clinical trial enrollment, into treatment plans for patients with cancer, Formulate strategies to prevent and/or manage PARP inhibitor–associated AEs.

    • 1 tim. 27 min
    Kurt A. Schalper, MD, PhD / Shanu Modi, MD - HER2 and HER3 Alterations as Therapeutic Targets of Increasing Significance in Solid Tumors: Implications for Pathology and Oncology Practice

    Kurt A. Schalper, MD, PhD / Shanu Modi, MD - HER2 and HER3 Alterations as Therapeutic Targets of Increasing Significance in Solid Tumors: Implications for Pathology and Oncology Practice

    Go online to PeerView.com/FFU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Modern precision oncology practice relies on detecting molecular alterations that drive specific cancers to target them with matched therapies that yield the best possible outcomes for patients. HER2 alterations are key therapeutic targets in breast cancer, as well as in gastric, colorectal, and non–small cell lung cancers, among other solid tumors. In addition to established HER2-targeted therapies, a number of new agents with unique mechanisms of action have recently received regulatory approval, and further investigations are ongoing. HER3 and TROP2 are also emerging therapeutic targets in several cancers for which novel therapeutics are being developed. This PeerView educational activity based on a recent web broadcast reviews relevant HER2 alterations along with HER3 and TROP2 as targets of interest in different tumors, assesses recent therapeutic advances, and provides practical guidance for optimal testing and interpretation of results to guide therapeutic decisions. Upon completion of this activity, participants should be better able to: Describe HER2, HER3, and other emerging therapeutically targetable alterations relevant in different cancers, and evolving testing approaches to identify these alterations, Discuss the characteristics, mechanisms of action, and clinical evidence on approved and emerging HER2-targeted therapeutic agents for the treatment of patients with HER2-altered solid tumors, as well as available data on emerging therapies targeting HER3 and other novel targets, Implement relevant methods and best practices for predictive testing to facilitate effective integration of the latest HER2-targeted and other promising therapies into personalized management plans for appropriate patients with solid tumors either in the context of clinical practice or clinical trials.

    • 51 min
    Matthew S. Johnson, MD, FSIR / Richard S. Finn, MD - At the Nexus of Locoregional and Systemic Liver Cancer Therapy: A Multidisciplinary Tumor Board on Improving Outcomes in Intermediate to Advanced HCC

    Matthew S. Johnson, MD, FSIR / Richard S. Finn, MD - At the Nexus of Locoregional and Systemic Liver Cancer Therapy: A Multidisciplinary Tumor Board on Improving Outcomes in Intermediate to Advanced HCC

    Go online to PeerView.com/DCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. [Activity_Description]

    • 41 min
    Michael R. Bishop, MD - Betting on CAR-T Cell Therapy: Expert Perspectives on Effective Integration Strategies and Achieving Improved Outcomes Across Hematologic Cancers

    Michael R. Bishop, MD - Betting on CAR-T Cell Therapy: Expert Perspectives on Effective Integration Strategies and Achieving Improved Outcomes Across Hematologic Cancers

    Go online to PeerView.com/MSF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hematologic oncology will deliver guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in settings such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. Panelists will draw on their personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, such as timely referral to specialized centers, management of unique adverse events, longer-term follow-up, and eligibility for enrollment in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Discuss up-to-date efficacy and safety evidence on adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells in leukemia and lymphoma, Analyze the role and benefits of CAR-T cell therapy in the treatment of patients with leukemia and lymphoma, particularly in patients eligible for clinical trials, Integrate approved and emerging CAR-T cell therapies into treatment plans in a safe and effective manner, including by referring patients to specialized centers and effectively managing unique adverse events.

    • 58 min

Mest populära podcaster inom Vetenskap

Andra som lyssnade prenumererar på